南新制药(688189) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue decreased by 23.00% to CNY 250,724,188.68 year-on-year[6] - Net profit attributable to shareholders decreased by 6.45% to CNY 24,678,193.46 compared to the same period last year[6] - Basic and diluted earnings per share decreased by 6.42% to CNY 0.1763[6] - Total operating revenue for Q1 2021 was ¥250,724,188.68, a decrease of 23.0% compared to ¥325,616,521.18 in Q1 2020[23] - Net profit for Q1 2021 was ¥25,161,556.74, a decrease of 11.7% from ¥28,512,421.77 in Q1 2020[25] - Total profit for Q1 2021 was ¥25,087,572.02, down 27.3% from ¥34,505,344.74 in Q1 2020[24] - The comprehensive income total for Q1 2021 was ¥25,161,556.74, a decrease from ¥28,512,421.77 in Q1 2020[25] Cash Flow - Net cash flow from operating activities was negative at CNY -68,941,958.20, a decrease of 1,036.69% year-on-year[6] - The net cash flow from operating activities for Q1 2021 was -68,941,958.20 RMB, a significant decrease compared to 7,360,155.36 RMB in Q1 2020[29] - The company reported a credit impairment loss of ¥-18,131,552.31 in Q1 2021, compared to ¥-2,840,994.02 in Q1 2020[24] - The company reported a cash outflow of 780,000,000.00 RMB for investment activities, reflecting ongoing investment strategies[31] - The net increase in cash and cash equivalents for Q1 2021 was -177,306,114.68 RMB, contrasting with an increase of 1,134,615,873.92 RMB in Q1 2020[30] Assets and Liabilities - Total assets increased by 8.68% to CNY 2,285,460,145.19 compared to the end of the previous year[6] - Total liabilities rose to CNY 635,393,283.51 from CNY 478,069,049.51, reflecting a significant increase of approximately 33.01%[17] - Current assets totaled CNY 1,923,963,603.73, up from CNY 1,729,597,539.22, indicating an increase of about 11.24%[16] - The total non-current assets amounted to CNY 361,496,541.46, down from CNY 373,376,815.23, indicating a decrease of about 3.19%[16] - The company’s retained earnings increased to CNY 160,563,274.62 from CNY 135,885,081.16, reflecting a growth of approximately 18.19%[18] Shareholder Information - The total number of shareholders was 7,262 at the end of the reporting period[10] - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., held 28.57% of the shares[10] Research and Development - R&D expenditure accounted for 11.43% of operating revenue, an increase of 4.68 percentage points compared to the previous year[6] - R&D expenses increased by 30.33% to ¥28,652,554.48, indicating a heightened focus on research and development[12] - Research and development expenses increased to ¥28,652,554.48 in Q1 2021, up 30.4% from ¥21,984,332.59 in Q1 2020[24] Inventory and Operating Costs - Inventory rose by 40.62% to ¥68,406,472.36, attributed to increased raw material stocking[12] - Operating costs decreased by 50.71% to ¥17,672,505.83, reflecting a decline in sales revenue while the proportion of new drugs increased[12] - Total operating costs for Q1 2021 were ¥216,036,295.34, down 25.2% from ¥288,773,259.12 in Q1 2020[24] Investment Income - Investment income reached ¥5,852,041.65, primarily from financial product returns[12] - Total cash inflow from investment activities was 664,578,069.05 RMB, primarily from cash recovered from investments[31]